Apelin‑13 alleviates diabetic nephropathy by enhancing nitric oxide production and suppressing kidney tissue fibrosis

Gao,Zhuo; Zhong,Xin; Tan,Ying-Xia; Liu,Dong

doi:10.3892/ijmm.2021.5008

Apelin‑13 alleviates diabetic nephropathy by enhancing nitric oxide production and suppressing kidney tissue fibrosis

Authors:
- Zhuo Gao
- Xin Zhong
- Ying-Xia Tan
- Dong Liu
View Affiliations

Affiliations: Department of Nephrology, Air Force Medical Center, Beijing 100142, P.R. China, Department of Nephrology, Longgang District Central Hospital of Shenzhen, Shenzhen, Guangdong 518116, P.R. China, Institute of Transfusion Medicine, Academy of Military Medical Sciences, Beijing 100850, P.R. China
Published online on: July 14, 2021 https://doi.org/10.3892/ijmm.2021.5008
Article Number: 175
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetes is a serious metabolic disease, and the kidney damage induced by diabetes also seriously affects the survival of patients. Apelin is a molecule that plays a crucial role in lipid metabolism, and recent studies have revealed that apelin‑13, a subtype of apelin, plays an important role in regulating blood glucose levels. However, the role of apelin‑13 in diabetic nephropathy remains unclear. In the present study, a rat model of diabetic nephropathy was constructed by the injection of streptozocin (STZ). During this process, these rats were injected with apelin‑13. The blood glucose, urine protein and insulin levels were determined weekly. Next, the expression of angiotensin domain type 1 receptor‑associated protein (APJ), endothelial nitric oxide synthase (eNOS), E‑cadherin and α‑smooth muscle actin (α‑SMA) in the kidney tissues was determined with western blotting. Then, the endothelial cells of glomerular vessels were cultured with high glucose medium. These cells were treated with apelin‑13 for 24 h. Finally, cell viability of these cells and the expression of APJ, eNOS, E‑cadherin and α‑SMA in these cells were determined with western blotting. As a result, treatment of apelin‑13 induced the lower levels of blood glucose and urine protein. In addition, application of apelin‑13 promoted the production of insulin and alleviated the insulin resistance. Treatment with apelin‑13 promoted the expression of APJ, eNOS and E‑cadherin while it suppressed the expression of α‑SMA in kidney tissues of rats and endothelial cells of glomerular vessels. Furthermore, application of apelin‑13 also promoted the cell viability of these cells. In conclusion, apelin‑13 relieved diabetic nephropathy by promoting the production of nitric oxide (NO) and alleviating the fibrosis of kidney tissues.

View Figures

View References

1	Yu SY, Dong B, Fang ZF, Hu XQ, Tang L and Zhou SH: Knockdown of lncRNA AK139328 alleviates myocardial ischaemia/reperfusion injury in diabetic mice via modulating miR-204-3p and inhibiting autophagy. J Cell Mol Med. 22:4886–4898. 2018. View Article : Google Scholar
2	Rowley WR and Bezold C: Creating public awareness: State 2025 diabetes forecasts. Popul Health Manag. 15:194–200. 2012. View Article : Google Scholar
3	Rowley WR, Bezold C, Arikan Y, Byrne E and Krohe S: Diabetes 2030: Insights from yesterday, today, and future trends. Popul Health Manag. 20:6–12. 2017. View Article : Google Scholar
4	American Diabetes Association: Standards of medical care in diabetes-2014. Diabetes Care. 37(Suppl 1): S5–S13. 2014. View Article : Google Scholar
5	Ahlqvist E, van Zuydam NR, Groop LC and McCarthy MI: The genetics of diabetic complications. Nat Rev Nephrol. 11:277–287. 2015. View Article : Google Scholar
6	Navarro-González JF, Jarque A, Muros M, Mora C and García J: Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev. 20:165–173. 2009. View Article : Google Scholar
7	Alvarez ML and Distefano JK: The role of non-coding RNAs in diabetic nephropathy: Potential applications as biomarkers for disease development and progression. Diabetes Res Clin Pract. 99:112013. View Article : Google Scholar
8	Del Ry S, Cabiati M, Raucci S, Simioniuc A, Caselli C, Prescimone T and Giannessi D: Sequencing and cardiac expression of Apelin in Sus Scrofa. Pharmacol Res. 60:314–319. 2009. View Article : Google Scholar
9	Fasshauer M and Blüher M: Adipokines in health and disease. Trends Pharmacol Sci. 36:461–470. 2015. View Article : Google Scholar
10	Lv D, Li H and Chen L: Apelin and APJ, a novel critical factor and therapeutic target for atherosclerosis. Acta Biochim Biophys Sin (Shanghai). 45:527–533. 2013. View Article : Google Scholar
11	Wysocka MB, Pietraszek-Gremplewicz K and Nowak D: The role of apelin in cardiovascular diseases, obesity and cancer. Front Physiol. 9:5572018. View Article : Google Scholar
12	Sentinelli F, Capoccia D, Bertoccini L, Barchetta I, Incani M, Coccia F, Manconi E, Lenzi A, Cossu E, Leonetti F, et al: Search for genetic variant in the apelin gene by resequencing and association study in European subjects. Genet Test Mol Biomarkers. 20:98–102. 2016. View Article : Google Scholar
13	Onalan E, Yakar B, Barım AO and Gursu MF: Serum apelin and resistin levels in patients with impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, and metabolic syndrome. Endokrynol Pol. 71:319–324. 2020.
14	Adki KM and Kulkarni YA: Potential biomarkers in diabetic retinopathy. Curr Diabetes Rev. 16:971–983. 2020. View Article : Google Scholar
15	Wu R, Zhu Z and Zhou D: VEGF, apelin and HO-1 in diabetic patients with retinopathy: A correlation analysis. BMC Ophthalmol. 20:3262020. View Article : Google Scholar
16	Yasir M, Senthilkumar GP, Jayashree K, Ramesh Babu K, Vadivelan M and Palanivel C: Association of serum omentin-1, apelin and chemerin concentrations with the presence and severity of diabetic retinopathy in type 2 diabetes mellitus patients. Arch Physiol Biochem. Nov 5–2019.Epub ahead of print. View Article : Google Scholar
17	Sabouri M, Norouzi J, Zarei Y, Sangani MH and Hooshmand Moghadam B: Comparing high-intensity interval training (HIIT) and continuous training on Apelin, APJ, NO, and cardiotrophin-1 in cardiac tissue of diabetic rats. J Diabetes Res. 2020:14725142020. View Article : Google Scholar
18	Dawood AF, Sabry MM, Estaphan SA, Mohamed EA, Younes SF, Rashed LA and Elzainy AW: Cross-talk between apelin and vasopressin in response to different osmotic stimuli in type 2 diabetic rats. J Biol Regul Homeost Agents. 32:1117–1127. 2018.
19	National Research Council (US) Committee for the Update of the Guide for the Care and use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. 8th edition. National Academies Press (US); Washington, DC: 2011
20	Chen Y, Lin L, Tao X, Song Y, Cui J and Wan J: The role of podocyte damage in the etiology of ischemia-reperfusion acute kidney injury and post-injury fibrosis. BMC Nephrol. 20:1062019. View Article : Google Scholar
21	Xue M, Shi Y, Pang A, Men L, Hu Y, Zhou P, Long G, Tian X, Wang R, Zhao Y, et al: Corin plays a protective role via upregulating MAPK and downregulating eNOS in diabetic nephropathy endothelial dysfunction. FASEB J. 34:95–106. 2020. View Article : Google Scholar
22	Rossi L and Gesualdo L: Diabetic nephropathy and cardiovascular risk. G Ital Nefrol. 34(Suppl 69): S104–S118. 2017.In Italian.
23	Van Krieken R and Krepinsky JC: Caveolin-1 in the pathogenesis of diabetic nephropathy: Potential therapeutic target? Curr Diab Rep. 17:192017. View Article : Google Scholar
24	Saran R, Robinson B, Abbott KC, Agodoa LYC, Bhave N, Bragg-Gresham J, Balkrishnan R, Dietrich X, Eckard A, Eggers PW, et al: US renal data system 2017 annual data report: Epidemiology of kidney disease in the United States. Am J Kidney Dis. 71(3 Suppl 1): A72018. View Article : Google Scholar
25	Khan NU, Lin J, Liu X, Li H, Lu W, Zhong Z, Zhang H, Waqas M and Shen L: Insights into predicting diabetic nephropathy using urinary biomarkers. Biochim Biophys Acta Proteins Proteom. 1868:1404752020. View Article : Google Scholar
26	Castan-Laurell I, El Boustany R, Pereira O, Potier L, Marre M, Fumeron F, Valet P, Gourdy P, Velho G and Roussel R: Plasma Apelin and risk of type 2 diabetes in a cohort from the community. Diabetes Care. 43:e15–e16. 2020. View Article : Google Scholar
27	Guo YY, Li T, Liu H, Tang L, Li YC, Hu HT, Su YF, Lin Y, Wang YY, Li C, et al: Circulating levels of Elabela and Apelin in the second and third trimesters of pregnancies with gestational diabetes mellitus. Gynecol Endocrinol. 36:890–894. 2020. View Article : Google Scholar
28	Tanday N, Irwin N, Moffett RC, Flatt PR and O'Harte FPM: Beneficial actions of a long-acting apelin analogue in diabetes are related to positive effects on islet cell turnover and transdifferentiation. Diabetes Obes Metab. 22. pp. 2468–2478. 2020, View Article : Google Scholar
29	Bae JH, Kwak SE, Lee JH, Yangjie Z and Song W: Does exercise-induced apelin affect sarcopenia? A systematic review and meta-analysis. Hormones (Athens). 18:383–393. 2019. View Article : Google Scholar
30	Sabry MM, Mahmoud MM, Shoukry HS, Rashed L, Kamar SS and Ahmed MM: Interactive effects of apelin, renin-angiotensin system and nitric oxide in treatment of obesity-induced type 2 diabetes mellitus in male albino rats. Arch Physiol Biochem. 125:244–254. 2019. View Article : Google Scholar
31	Ji B, Shang L, Wang C, Wan L, Cheng B and Chen J: Roles for heterodimerization of APJ and B2R in promoting cell proliferation via ERK1/2-eNOS signaling pathway. Cell Signal. 73:1096712020. View Article : Google Scholar
32	Nagib AM, El-Diasty A, El Husseny MA, El-Gamal EM, Abbas MH, Refaie AF and Foudas MA: Apelin and new-onset diabetes after transplant in living kidney allograft recipients. Exp Clin Transplant. 13:319–323. 2015.
33	Huang Z, Luo X, Liu M and Chen L: Function and regulation of apelin/APJ system in digestive physiology and pathology. J Cell Physiol. 234:7796–7810. 2019. View Article : Google Scholar
34	Wakisaka M, Kamouchi M and Kitazono T: Lessons from the trials for the desirable effects of sodium glucose Co-transporter 2 inhibitors on diabetic cardiovascular events and renal dysfunction. Int J Mol Sci. 20:56682019. View Article : Google Scholar
35	Li A, Peng R, Sun Y, Liu H, Peng H and Zhang Z: LincRNA 1700020I14Rik alleviates cell proliferation and fibrosis in diabetic nephropathy via miR-34a-5p/Sirt1/HIF-1α signaling. Cell Death Dis. 9:4612018. View Article : Google Scholar
36	Zhou X, Ma L, Habibi J, Whaley-Connell A, Hayden MR, Tilmon RD, Brown AN, Kim JA, Demarco VG and Sowers JR: Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension. 55:880–888. 2010. View Article : Google Scholar
37	Wada J and Makino H: Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol. 12:13–26. 2016. View Article : Google Scholar
38	Niewczas MA, Pavkov ME, Skupien J, Smiles A, Md Dom ZI, Wilson JM, Park J, Nair V, Schlafly A, Saulnier PJ, et al: A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med. 25:805–813. 2019. View Article : Google Scholar
39	Mou Z, Feng Z, Xu Z, Zhuang F, Zheng X, Li X, Qian J and Liang G: Schisandrin B alleviates diabetic nephropathy through suppressing excessive inflammation and oxidative stress. Biochem Biophys Res Commun. 508:243–249. 2019. View Article : Google Scholar
40	Al Hroob AM, Abukhalil MH, Alghonmeen RD and Mahmoud AM: Ginger alleviates hyperglycemia-induced oxidative stress, inflammation and apoptosis and protects rats against diabetic nephropathy. Biomed Pharmacother. 106:381–389. 2018. View Article : Google Scholar